Need to keep on prime of the science and politics driving biotech at this time? Enroll to get our biotech e-newsletter in your inbox.
ARPA-H has unveiled a $160 million effort to hurry bespoke gene-editing therapies for uncommon illnesses into the clinic. In the meantime, Roche has deserted two Huntington’s gene-silencing medication after disappointing information, and drugmakers have stepped in to advertise Medicare’s new weight problems drug low cost program.
I bought espresso with my cousin this morning right here in SF. Earlier than leaving for his job at an AI behemoth, he stated the bone-chilling July gloom is ideal “working climate.”
This text is unique to STAT+ subscribers
Unlock this text — plus in-depth evaluation, newsletters, premium occasions, and information alerts.
Have already got an account? Log in
View All Plans
